Catalytic properties of botulinum neurotoxin subtypes A3 and A4
- PMID: 19256469
- PMCID: PMC2701208
- DOI: 10.1021/bi801686b
Catalytic properties of botulinum neurotoxin subtypes A3 and A4
Abstract
Botulinum toxins (BoNT) are zinc proteases (serotypes A-G) which cause flaccid paralysis through the cleavage of SNARE proteins within motor neurons. BoNT/A was originally organized into two subtypes, BoNT/A1 and BoNT/A2, which are approximately 95% homologous and possess similar catalytic activities. Subsequently, two additional subtypes were identified, BoNT/A3 (Loch Maree) and BoNT/A4 (657Ba), which are 81 and 88% homologous with BoNT/A1, respectively. Alignment studies predicted that BoNT/A3 and BoNT/A4 were sufficiently different from BoNT/A1 to affect SNAP25 binding and cleavage. Recombinant light chain (LC) of BoNT/A3 (LC/A3) and BoNT/A4 (LC/A4) were subjected to biochemical analysis. LC/A3 cleaved SNAP25 at 50% of the rate of LC/A1 but cleaved SNAPtide at a faster rate than LC/A1, while LC/A4 cleaved SNAP25 and SNAPtide at slower rates than LC/A1. LC/A3 and LC/A4 had similar K(m) values for SNAP25 relative to LC/A1, while the k(cat) for LC/A4 was 10-fold slower than that for LC/A1, suggesting a defect in substrate cleavage. Neither LC/A3 nor LC/A4 possessed autocatalytic activity, a property of LC/A1 and LC/A2. Thus, the four subtypes of BoNT/A bind SNAP25 with similar affinity but have different catalytic capacities for SNAP25 cleavage, SNAPtide cleavage, and autocatalysis. The catalytic properties identified among the subtypes of LC/A may influence strategies for the development of small molecule or peptide inhibitors as therapies against botulism.
Figures





Similar articles
-
A Comprehensive Structural Analysis of Clostridium botulinum Neurotoxin A Cell-Binding Domain from Different Subtypes.Toxins (Basel). 2023 Jan 18;15(2):92. doi: 10.3390/toxins15020092. Toxins (Basel). 2023. PMID: 36828407 Free PMC article. Review.
-
High resolution crystal structures of Clostridium botulinum neurotoxin A3 and A4 binding domains.J Struct Biol. 2018 May;202(2):113-117. doi: 10.1016/j.jsb.2017.12.010. Epub 2017 Dec 26. J Struct Biol. 2018. PMID: 29288126
-
A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4.J Mol Biol. 2006 Sep 29;362(4):733-42. doi: 10.1016/j.jmb.2006.07.040. Epub 2006 Jul 27. J Mol Biol. 2006. PMID: 16938310
-
Holotoxin Activity of Botulinum Neurotoxin Subtype A4 Originating from a Nontoxigenic Clostridium botulinum Expression System.Appl Environ Microbiol. 2014 Dec;80(23):7415-22. doi: 10.1128/AEM.01795-14. Epub 2014 Sep 19. Appl Environ Microbiol. 2014. PMID: 25239905 Free PMC article.
-
8-Hydroxyquinoline and hydroxamic acid inhibitors of botulinum neurotoxin BoNT/A.Curr Top Med Chem. 2014;14(18):2094-102. doi: 10.2174/1568026614666141022095114. Curr Top Med Chem. 2014. PMID: 25335884 Review.
Cited by
-
A Comprehensive Structural Analysis of Clostridium botulinum Neurotoxin A Cell-Binding Domain from Different Subtypes.Toxins (Basel). 2023 Jan 18;15(2):92. doi: 10.3390/toxins15020092. Toxins (Basel). 2023. PMID: 36828407 Free PMC article. Review.
-
Subunit vaccine efficacy against Botulinum neurotoxin subtypes.Vaccine. 2011 Oct 13;29(44):7688-95. doi: 10.1016/j.vaccine.2011.07.134. Epub 2011 Aug 10. Vaccine. 2011. PMID: 21839134 Free PMC article.
-
Isolation and functional characterization of the novel Clostridium botulinum neurotoxin A8 subtype.PLoS One. 2015 Feb 6;10(2):e0116381. doi: 10.1371/journal.pone.0116381. eCollection 2015. PLoS One. 2015. PMID: 25658638 Free PMC article.
-
Crystal structure of the catalytic domain of botulinum neurotoxin subtype A3.J Biol Chem. 2021 Jan-Jun;296:100684. doi: 10.1016/j.jbc.2021.100684. Epub 2021 Apr 21. J Biol Chem. 2021. PMID: 33891946 Free PMC article.
-
Cleavage of SNAP25 and its shorter versions by the protease domain of serotype A botulinum neurotoxin.PLoS One. 2014 Apr 25;9(4):e95188. doi: 10.1371/journal.pone.0095188. eCollection 2014. PLoS One. 2014. PMID: 24769566 Free PMC article.
References
-
- Shiva G, Rossetti O, Santucci A, DasGupta RR, Montecucco C. Botulinum Neurotoxins are Zinc Proteases. Journal of Biological Chemistry. 1992;267:23479–23483. - PubMed
-
- Binz T, Blasi J, Yamasaki S, Baumeister A, Link E, Sudhof TC, Jahn R, Niemann H. Proteolysis of SNAP-25 by types E and A botulinal neurotoxins. J Biol Chem. 1994;269:1617–1620. - PubMed
-
- Naumann M, So Y, Argoff CE, Childers MK, Dykstra DD, Gronseth GS, Jabbari B, Kaufmann HC, Schurch B, Silberstein SD, Simpson DM. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): Reports of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70:1707–1714. - PubMed
-
- Bandyopadhyay S, Clark AW, DasGupta BR, Sathyamoorthy V. Role of the heavy and light chains of botulinum neurotoxin in neuromuscular paralysis. J Biol Chem. 1989;262:2660–2663. - PubMed
-
- Lacy DB, Stevens RC. Sequence homology and structural analysis of the clostridial neurotoxins. J Mol Biol. 1999;291:1091–1104. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous